Alloksys announces new Supervisory Board member, Kevin Driscoll

Wageningen, 23 October 2017- Alloksys Life Sciences announced today that Kevin Driscoll has been appointed to its Supervisory Board.

Dr. Driscoll is a proven Healthcare executive with 30 years experience leading all aspects of innovation and R&D across the prescription drug, OTC drug, and food supplement businesses. He has a strong track record delivering healthcare innovation to market including on brands such as: Actonel; ratiopharm; Prilosec; Vicks; Metamucil; and Swisse Wellness. Dr. Driscoll has built and led global technical organizations, including large multifunctional and virtual start-ups, most recently he was a founding member of PGT Healthcare, a global JV between Teva Pharmaceuticals and P&G.

“We are pleased to welcome Dr. Driscoll to Alloksys’ Supervisory Board,” said Ton Bolier, Chairman of the Supervisory Board. “His extensive experience in R&D management will benefit us in guiding the phase lll drug candidate to the market, as well as selecting new early stage development programs.”

“The science supporting the application of alkaline phosphatase for the treatment of a variety of disorders involving ischemia and inflammation is compelling. I am very pleased to join Alloksys’ Supervisory Board and work with the Alloksys Team to advance their alkaline phosphatase therapeutics through the clinic and to patients” said Dr. Driscoll.

About Alloksys Life Sciences
Alloksys Life Sciences is a Dutch company that develops RESCAP (RESCuing Alkaline Phosphatase) as a biologic therapeutic for the treatment of indications associated with acute ischemic injury and inflammation. The company’s lead program is currently in Phase llb/lll clinical trial in cardiothoracic surgery. This pivotal trial aims to demonstrate reduction in acute kidney injury peri- & post- heart surgery in more than 1250 patients.

For more information on this press release, please contact Xiaofei Zhang at +31 (0) 317 466 250,